Top Markets
Coin of the day
TCR2 Therapeutics Inc. TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.

TCRR
Kedudukan dalam Saham #27034
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on... TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
Harga Saham
$1.48
Disegerakkan terakhir: 2023-05-31
Modal Pasaran
$35.54M
Perubahan (1 hari)
-5.73%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan TCR2 Therapeutics Inc. (TCRR)

Kategori

Sejarah pecahan saham untuk TCR2 Therapeutics Inc. (TCRR)
Saham TCR2 Therapeutics Inc. (simbol: TCRR) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Aug 20, 2026.
Satu saham TCRR yang dibeli sebelum Aug 20, 2026 kini bersamaan dengan 0 saham TCRR.
Senarai pecahan saham
Tahun Pecahan Gandaan Gandaan Kumulatif
Tidak cukup data untuk tarikh yang disediakan.
Pecahan saham untuk syarikat pesaing atau serupa
Syarikat Bilangan pecahan saham Gandaan Kumulatif Negara
1 x2
US
0 -
US
0 -
NL
1 x3
AU
0 -
CH